Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric shocks + chemo: new hope for inoperable bone tumors?

NCT ID NCT07323017

Disease control Sponsor: Costantino Errani Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well electrochemotherapy (using electric pulses to boost chemotherapy) works for bone tumors that can't be removed with surgery. Researchers will track tumor size changes and pain levels in 60 patients over 12 months. The goal is to see if this treatment can control the disease and improve quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include patients older than 2 years with a diagnosis of musculoskeletal tumors who are indicated for electrochemotherapy, treated at the Rizzoli Orthopaedic Institute in Bologna and followed during outpatient follow-up. Data will be collected from medical records, outpatient reports, and imaging studies (CT, X-ray, MRI, and/or PET). The retrospective part will include patients treated at the Rizzoli Orthopaedic Institute from January 1, 2024, to the date of study approval. The prospective part will enroll patients meeting the inclusion criteria who will be treated from the study start date until December 31, 2030.

Ages

2 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of both sexes with a histological diagnosis of a primary musculoskeletal tumor, either benign or malignant, located outside the abdominal cavity (trunk and limbs) * Indication for electrochemotherapy due to one of the following conditions: 1. Clinical conditions contraindicating surgery 2. Tumor not surgically resectable * Patients treated with electrochemotherapy at the Rizzoli Orthopaedic Institute: 1. From 01/01/2024 to the date of study approval for the retrospective phase 2. From the date of study approval to 12/31/2030 for the prospective phase * Retrospectively treated patients with a minimum follow-up of at least 3 months * Age ≥ 2 years at the time of treatment * Availability of clinical and instrumental data Exclusion Criteria: • Failure to meet at least one of the inclusion criteria

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bone cancer bone neoplasm connective and soft tissue neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone tumors

Contacts and locations

Locations

  • Irccs Istituto Ortopedico Rizzoli

    Bologna, Emilia-Romagna, 40134, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.